Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories
Twist Bioscience (NASDAQ: TWST) has partnered with Stanford University's Innovative Medicines Accelerator to provide access to its antibody discovery services and its innovative 'Library of Libraries.' This collaboration will enable Stanford researchers to utilize Twist’s advanced synthetic antibody libraries for various therapeutic targets. Twist will receive technology access fees and share in revenue from outlicensed antibodies. The first project aims to discover novel antibodies targeting a neuroscience application. The partnership showcases Twist's commitment to advancing biologics discovery through collaboration.
- Collaboration with Stanford enhances Twist's positioning in antibody discovery.
- Access to 'Library of Libraries' provides researchers with cutting-edge tools.
- Revenue potential from technology access fees and antibody outlicensing.
- None.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has signed an agreement enabling multiple academic laboratories at Stanford University to access Twist Bioscience’s innovative antibody discovery and optimization services as well as its unique “Library of Libraries” for biologics discovery.
Through Stanford’s Innovative Medicines Accelerator (IMA), its researchers will be able to access Twist’s “Library of Libraries,” a range of pre-constructed and validated synthetic antibody libraries, as well as proprietary discovery and optimization capabilities of Twist Biopharma, a division of Twist Bioscience, to accelerate antibody discovery against a wide range of therapeutic targets.
Each academic laboratory working through the IMA may independently access the “Library of Libraries” and once accessed, has the option to use this robust discovery tool to discover new biologics against their specified target, or to have Twist Biopharma conduct the discovery and optimization work. Twist will receive technology access fees for each lab that accesses the “Library of Libraries” and will share in revenue of all antibodies that are outlicensed for further development. The first project under the agreement focuses on discovery of novel antibodies to a neuroscience target from the lab of Katrin Andreasson, M.D., professor of neurology at the Stanford University School of Medicine.
“At Twist, we bring a differentiated approach to biologics discovery that can be applied to a wide range of therapeutic targets and diseases,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We excel in pushing the boundaries of possibility and actively engage in opportunities where our expertise in DNA synthesis provides a competitive advantage. Working with Stanford University’s Innovative Medicines Accelerator provides a perfect example of the exponential impact of pairing our drug discovery and optimization capabilities with academic excellence, ultimately leading to innovative treatment options.”
By leveraging Twist’s unique ability to manufacture DNA at scale, researchers can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This “Library of Libraries” gives Twist’s partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation, the ability of the collaboration to successfully accelerate antibody discovery against a wide range of therapeutic targets, to lead to innovative treatment options, and to expedite antibody discovery by decreasing risk, increasing speed and lowering failure rate for therapeutic development, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on February 9, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005402/en/
FAQ
What is Twist Bioscience's recent partnership about?
What will Stanford researchers gain from the collaboration with Twist Bioscience?
What is the first project under the Twist and Stanford agreement?
How will Twist Bioscience benefit financially from this agreement?
What is the significance of Twist's 'Library of Libraries'?
